VivoSeq
Other

Pregabalin

0

Pipeline Programs

3

Active Trials

5

Companies Involved

Pregabalin is an early-stage landscape with 0 programs across 5 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Pfizer, AstraZeneca.

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

84/100

Attrition Rate

13/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

71

clinical trials

Completed49 · 69%
Unknown status10 · 14%
Terminated5 · 7%
Withdrawn4 · 6%
Recruiting2 · 3%
Not yet recruiting1 · 1%

Trial Activity

71 trials

The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination
Not yet recruiting··Phase 4·NCT06401499·140 enrolled
Comparison of Pregabalin Versus Gabapentin as Pre-emptive Analgesic
Completed··N/A·NCT07389551·142 enrolled
Pregabalin vs. Gabapentin on Reducing Opioid Usage
Completed··Phase 4·NCT04705480·109 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)